Hikma Pharmaceuticals PLC (LON:HIK) Investors: Peel Hunt Reaffirms “Hold” Rating, Sees GBX 1180.00/Share; Centerstate Banks (CSFL) Has 1.33 Sentiment

CenterState Bank Corporation operates as the holding firm for CenterState Bank of Florida, N.A. that provides various consumer and commercial banking services to individuals, businesses, and industries in Florida. The company has market cap of $2.22 billion. The companyÂ’s deposit products include savings, demand, negotiable order of withdrawal, and money market deposit accounts, as well as certificates of deposit and time deposits. It has a 28.31 P/E ratio. It also offers real estate loans to individuals and businesses for the purchase, improvement of, or investment in real estate; construction of single-family residential and commercial units; and development of single-family residential building lots.

Peel Hunt have a GBX 1180.00 target price per share on the stock. The target price per share means a potential upside of 30.75% from Hikma Pharmaceuticals PLC (LON:HIK)‘s last stock price. This rating was released in a report on 15 February.

The stock increased 2.75% or GBX 24.6 during the last trading session, reaching GBX 917.8. About 35,962 shares traded. Hikma Pharmaceuticals PLC (LON:HIK) has 0.00% since February 15, 2017 and is . It has underperformed by 16.70% the S&P500.

Among 15 analysts covering Hikma Pharmaceuticals PLC (LON:HIK), 7 have Buy rating, 2 Sell and 6 Hold. Therefore 47% are positive. Hikma Pharmaceuticals PLC has GBX 3400 highest and GBX 865 lowest target. GBX 1453.14’s average target is 58.33% above currents GBX 917.8 stock price. Hikma Pharmaceuticals PLC had 165 analyst reports since July 29, 2015 according to SRatingsIntel. The firm has “Buy” rating by Jefferies given on Wednesday, March 16. The company was maintained on Tuesday, April 4 by Stifel Nicolaus. The firm has “Neutral” rating given on Tuesday, June 27 by JP Morgan. The rating was downgraded by JP Morgan on Thursday, March 16 to “Neutral”. The stock of Hikma Pharmaceuticals PLC (LON:HIK) earned “Neutral” rating by Citigroup on Wednesday, June 28. The rating was maintained by Numis Securities with “Buy” on Wednesday, December 20. The rating was downgraded by Numis Securities to “Add” on Friday, March 10. The firm has “Overweight” rating by JP Morgan given on Tuesday, November 10. The rating was maintained by JP Morgan with “Neutral” on Monday, May 22. Peel Hunt maintained Hikma Pharmaceuticals PLC (LON:HIK) rating on Monday, August 21. Peel Hunt has “Hold” rating and GBX 1390 target.

Hikma Pharmaceuticals PLC develops, makes, and markets a range of generic, branded, and in-licensed pharmaceutical products in solid, semi-solid, liquid, and injectable final dosage forms worldwide. The company has market cap of 2.21 billion GBP. It operates through three divisions: Branded, Injectables, and Generic. It has a 13.3 P/E ratio. The Branded segment offers 377 products in 1,125 dosage forms and strengths in the anti-infective, cardiovascular, diabetes, central nervous system , gastro-intestinal, oncology, respiratory, and miscellaneous therapeutic areas.

Since January 1, 0001, it had 0 insider purchases, and 2 sales for $599,477 activity.

The stock increased 2.09% or $0.55 during the last trading session, reaching $26.89. About 722,654 shares traded or 30.57% up from the average. CenterState Bank Corporation (CSFL) has risen 57.47% since February 15, 2017 and is uptrending. It has outperformed by 40.77% the S&P500.

Free Email Newsletter

Enter your email address below to get the latest news and analysts’ ratings for your stocks with our free daily email newsletter: